Results 11 to 20 of about 1,651 (123)

Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome following Dalbavancin and Oritavancin Administration in a Patient with Osteomyelitis [PDF]

Case Reports in Dermatology
Introduction: Dalbavancin and oritavancin are newer long-acting antibiotics with potent activity against gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA). To our knowledge, there have been no reported cases
Jina Bai, Emily Frech Preciado, Mary Baxter Harlow, Nina Blank   +3 more
doaj   +2 more sources

Difficult-to-Treat Skin and Soft Tissue Infections Caused by Panton-Valentine Leukocidin-Producing Community-Associated Methicillin-Resistant Staphylococcus aureus: A Case Series [PDF]

Infectious Disease Reports
Background: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) has emerged as a genetically distinct lineage from healthcare-associated MRSA (HA-MRSA), often producing Panton-Valentine leukocidin (PVL) and causing severe skin and ...
Luca Pipitò, Chiara Vincenza Mazzola, Giulio D’Agati, Eleonora Bono, Raffaella Rubino, Silvia Bonura, Claudia Gioè, Teresa Fasciana, Antonio Cascio   +8 more
doaj   +2 more sources

A Comparative Review of the Pharmacology of Dalbavancin and Oritavancin for Gram-Positive Infections: Birds of a Feather or Apples and Oranges? [PDF]

Infectious Diseases and Therapy
The clinical landscape of Gram-positive infections has been reshaped with the introduction of long-acting lipoglycopeptides, particularly dalbavancin and oritavancin.
Maytham Hussein, James Barclay, Mark Baker, Yuezhou Wu, Varsha J. Thombare, Nitin Patil, Ananya B. Murthy, Rajnikant Sharma, Gauri G. Rao, Mark A. T. Blaskovich, Jian Li, Tony Velkov   +11 more
doaj   +2 more sources

One-Shot, One Opportunity: Retrospective Observational Study on Long-Acting Antibiotics for SSTIs in the Emergency Room—A Real-Life Experience [PDF]

Pathogens
Background: Skin and soft tissue infections (SSTIs) are a major cause of emergency room (ER) visits and hospitalizations. Long-acting lipoglycopeptides (LALs), such as dalbavancin and oritavancin, offer potential for early discharge and outpatient ...
Giacomo Ciusa, Giuseppe Pipitone, Alessandro Mancuso, Stefano Agrenzano, Claudia Imburgia, Agostino Massimo Geraci, Alberto D’Alcamo, Luisa Moscarelli, Antonio Cascio, Chiara Iaria   +9 more
doaj   +2 more sources

Improved economic and clinical outcomes with oritavancin versus a comparator group for treatment of acute bacterial skin and skin structure infections in a community hospital.

PLoS ONE, 2021
BackgroundOritavancin is a lipoglycopeptide antibiotic with in vitro bactericidal activity against gram-positive pathogens indicated for use in adults with acute bacterial skin and skin structure infections (ABSSSI).
Kimberly Saddler, Jason Zhang, Jennifer Sul, Pruthvi Patel, Miriams Castro-Lainez, Mark L Stevens, Sheryl Kosler, Emily Lowery, Miguel Sierra-Hoffman   +8 more
doaj   +1 more source

Review of oritavancin for the treatment of acute bacterial skin and skin structure infections [PDF]

Farmacia Hospitalaria, 2018
Objective: To assess critically oritavancin, a second-generation lipoglycopeptide, for the treatment of Acute Bacterial Skin and Skin Structure Infections caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus ...
Ana Alejandra García Robles, Eduardo López Briz, María Dolores Fraga Fuentes, Rocío Asensi Diez, Jesús Francisco Sierra Sánchez   +4 more
doaj   +1 more source

In Vitro and In Vivo Studies of Oritavancin and Fosfomycin Synergism against Vancomycin-Resistant Enterococcus faecium

Antibiotics, 2022
Therapeutic options for infections caused by vancomycin-resistant enterococci are currently suboptimal. Combination regimens where fosfomycin is used alongside existing treatments are emerging given the proven synergistic potential and PK/PD properties ...
Cristina Lagatolla, Jai W. Mehat, Roberto Marcello La Ragione, Roberto Luzzati, Stefano Di Bella   +4 more
doaj   +1 more source

Molecular dynamics simulations of the secondary-binding site in disaccharide-modified glycopeptide antibiotics

Scientific Reports, 2022
Oritavancin is a semisynthetic glycopeptide antibiotic used to treat severe infections by multidrug-resistant Gram-positive pathogens. Oritavancin is known to be a thousand times more potent than vancomycin against Gram-positive bacteria due to the ...
Olatunde P. Olademehin, Kevin L. Shuford, Sung J. Kim   +2 more
doaj   +1 more source

Clinical Outcomes and Economic Impact of Oritavancin for Gram-Positive Infections: A Single Academic Medical Center Health System Experience

Drugs - Real World Outcomes, 2020
Background Vancomycin treatment of complicated Gram-positive infections is associated with laboratory monitoring, nephrotoxicity, and multiple daily dosing.
Lauren E. Brownell, Meagan L. Adamsick, Erin K. McCreary, Joshua P. Vanderloo, Erika J. Ernst, Emily R. Jackson, Lucas T Schulz   +6 more
doaj   +1 more source

The Real-World Economic and Clinical Management of Adult Patients with Skin and Soft Tissue Infections (SSTIs) with Oritavancin: Data from Two Multicenter Observational Cohort Studies

Drugs - Real World Outcomes, 2020
Background Oritavancin is a FDA-approved single-dose IV therapy for the treatment of acute bacterial skin and skin structure infections caused (or suspected to be caused) by certain Gram-positive pathogens, including methicillin-resistant Staphylococcus ...
Sandy Estrada, Thomas P. Lodise, Glenn S. Tillotson, Dino Delaportas   +3 more
doaj   +1 more source